Assembly Biosciences, Inc. Deferred Revenue Recognized
Assembly Biosciences, Inc. (ASMB) reported Deferred Revenue Recognized of $8.21 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-05-07
- Assembly Biosciences, Inc. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $8.21M.
- Assembly Biosciences, Inc. contract with customer, liability, revenue recognized for the quarter ending 2024-09-30 was $6.84M.
- Assembly Biosciences, Inc. contract with customer, liability, revenue recognized for the quarter ending 2024-06-30 was $8.53M.
- Assembly Biosciences, Inc. contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was $5.79M.
- Assembly Biosciences, Inc. contract with customer, liability, revenue recognized for fiscal 2024 was $28.27M, a 934.43% increase from fiscal 2023.
- Assembly Biosciences, Inc. contract with customer, liability, revenue recognized for fiscal 2023 was $2.73M.
- Assembly Biosciences, Inc. contract with customer, liability, revenue recognized for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Assembly Biosciences, Inc. contract with customer, liability, revenue recognized for fiscal 2021 was $6.25M, a 83.12% decline from fiscal 2020.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-03-31 | $8.21M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $28.27M 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $6.84M 10-Q · filed 2024-11-07 | $21.16M 10-Q · filed 2024-11-07 | ||
| 2024-06-30 | $8.53M 10-Q · filed 2024-08-08 | $14.32M 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | $5.79M 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $2.73M 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-28 | |||
| 2021-12-31 | $6.25M 10-K · filed 2023-03-22 | |||
| 2020-12-31 | $37.05M 10-K · filed 2022-03-11 | |||
| 2020-06-30 | $36.04M 10-Q · filed 2020-08-05 | $37.05M 10-Q · filed 2020-08-05 | ||
| 2020-03-31 | $1.01M 10-Q · filed 2020-05-08 | |||
| 2019-12-31 | $3.61M 10-K · filed 2021-02-25 | |||
| 2019-09-30 | $1.25M 10-Q · filed 2019-11-07 | $2.24M 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | $137.00K 10-Q · filed 2020-08-05 | $996.00K 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $859.00K 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | $5.13M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $1.67M 10-Q · filed 2019-11-07 | $3.86M 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |